Scholarlink

Background <p>Sudden sensorineural hearing loss (SSNHL) is an otologic emergency commonly treated with corticosteroids; however, hearing recovery remains variable. Platelet-rich plasma (PRP), owing to its regenerative and angiogenic properties, has emerged as a potential therapeutic alternative. This study compared the short-term audiological outcomes of intratympanic PRP and intratympanic dexamethasone in patients with unilateral SSNHL.</p> Methods <p>This retrospective comparative study included 50 patients with unilateral SSNHL treated at a tertiary care centre between 2023 and 2025. Patients were divided into two groups: intratympanic dexamethasone (n=25) and intratympanic PRP (n=25). Injections were administered twice weekly for 2 weeks. Pure tone audiometry (PTA) was assessed at baseline and 1 month. The primary outcome was change in PTA, and hearing improvement was defined as a gain of&gt; 10 dB.</p> Results <p>This retrospective comparative study included 50 patients with unilateral SSNHL treated at a tertiary care center between 2023 and 2025. Patients received either intratympanic dexamethasone (4 mg/mL; n=25) or intratympanic PRP (n=25), in addition to standard systemic therapy. Four intratympanic injections were administered over two weeks. Pure tone audiometry (PTA) was performed at baseline and one month after treatment initiation. Baseline PTA was comparable between groups (68.4 ± 18.2 dB vs 65.2 ± 17.6 dB; p=0.56). At one month, the PRP group demonstrated significantly better hearing outcomes than the steroid group, with lower mean PTA (34.8 ± 12.9 dB vs 48.6 ± 16.5 dB; p=0.028) and greater mean hearing gain (30.4 ± 11.2 dB vs 19.8 ± 10.4 dB; p=0.028). A higher proportion of PRP-treated patients achieved mild residual hearing loss (60% vs 32%). No serious adverse events were observed in either group.</p> Conclusions <p>Intratympanic PRP was associated with greater short-term hearing improvement compared with intratympanic dexamethasone in patients with unilateral SSNHL. Although these findings suggest that PRP may represent a promising biologic treatment option, larger prospective randomized controlled trials with longer follow-up are required to confirm its efficacy and establish optimal treatment protocols.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging biological therapy vs. conventional steroid treatment in unilateral sudden sensorineural hearing loss (SSNHL) : a comparative study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Kirtika Gupta,
  • Bhupesh Gupta,
  • Hashbun Khan,
  • Ginni Datta,
  • Bhushan Chauhan,
  • Harshit Chawla,
  • Cynthia Kaur

摘要

Background

Sudden sensorineural hearing loss (SSNHL) is an otologic emergency commonly treated with corticosteroids; however, hearing recovery remains variable. Platelet-rich plasma (PRP), owing to its regenerative and angiogenic properties, has emerged as a potential therapeutic alternative. This study compared the short-term audiological outcomes of intratympanic PRP and intratympanic dexamethasone in patients with unilateral SSNHL.

Methods

This retrospective comparative study included 50 patients with unilateral SSNHL treated at a tertiary care centre between 2023 and 2025. Patients were divided into two groups: intratympanic dexamethasone (n=25) and intratympanic PRP (n=25). Injections were administered twice weekly for 2 weeks. Pure tone audiometry (PTA) was assessed at baseline and 1 month. The primary outcome was change in PTA, and hearing improvement was defined as a gain of> 10 dB.

Results

This retrospective comparative study included 50 patients with unilateral SSNHL treated at a tertiary care center between 2023 and 2025. Patients received either intratympanic dexamethasone (4 mg/mL; n=25) or intratympanic PRP (n=25), in addition to standard systemic therapy. Four intratympanic injections were administered over two weeks. Pure tone audiometry (PTA) was performed at baseline and one month after treatment initiation. Baseline PTA was comparable between groups (68.4 ± 18.2 dB vs 65.2 ± 17.6 dB; p=0.56). At one month, the PRP group demonstrated significantly better hearing outcomes than the steroid group, with lower mean PTA (34.8 ± 12.9 dB vs 48.6 ± 16.5 dB; p=0.028) and greater mean hearing gain (30.4 ± 11.2 dB vs 19.8 ± 10.4 dB; p=0.028). A higher proportion of PRP-treated patients achieved mild residual hearing loss (60% vs 32%). No serious adverse events were observed in either group.

Conclusions

Intratympanic PRP was associated with greater short-term hearing improvement compared with intratympanic dexamethasone in patients with unilateral SSNHL. Although these findings suggest that PRP may represent a promising biologic treatment option, larger prospective randomized controlled trials with longer follow-up are required to confirm its efficacy and establish optimal treatment protocols.